American Journal of Ophthalmology
Volume 145, Issue 1 , Pages 12-22.e10 , January 2008

Characteristics of Untreated AIDS-related Cytomegalovirus Retinitis. II. Findings in the Era of Highly Active Antiretroviral Therapy (1997 to 2000)

  • Gary N. Holland

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • Corresponding Author InformationInquiries to Gary N. Holland, Jules Stein Eye Institute, 100 Stein Plaza UCLA, Los Angeles, CA 90095
    • ,
  • Jean D. Vaudaux

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Kevin M. Shiramizu

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Fei Yu

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • David T. Goldenberg

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Anurag Gupta

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Margrit Carlson

      Affiliations

    • Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
    • ,
  • Russell W. Read

      Affiliations

    • Doheny Eye Institute and Department of Ophthalmology, Keck USC School of Medicine, Los Angeles, California
    • ,
  • Roger D. Novack

      Affiliations

    • Ocular Inflammatory Disease Center, the Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
    • Retina-Vitreous Associates Medical Group, Beverly Hills, California
    • ,
  • Baruch D. Kuppermann

      Affiliations

    • Department of Ophthalmology, University of California, Irvine, Irvine, California, and the University of California, Irvine, Medical Center, Orange, California.
    • ,
  • Southern California HIV/Eye Consortium

,Accepted 17 September 2007.

References 

  1. Holland GN, Vaudaux JD, Jeng SM, et al. Characteristics of untreated AIDS-related cytomegalovirus retinitis (I. Findings before the era of highly active antiretroviral therapy (1988 to 1994)). Am J Ophthalmol. 2008;145:5–11
  2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection (HIV Outpatient Study Investigators). N Engl J Med. 1998;338:853–860
  3. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol. 1997;124:227–233
  4. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994–1997. AIDS. 1998;12:1931–1933
  5. Doan S, Cochereau I, Guvenisik N, et al. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Am J Ophthalmol. 1999;128:250–251
  6. Jabs DA, van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133:48–61
  7. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443–1445
  8. Holland GN. New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy. Ocul Immunol Inflamm. 1999;7:179–188
  9. Nussenblatt RB, Lane HC. Human immunodeficiency virus disease: changing patterns of intraocular inflammation. Am J Ophthalmol. 1998;125:374–382
  10. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817–829
  11. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol. 1997;124:199–205
  12. Whitcup SM, Cunningham ET, Polis MA, Fortin E. Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy. Br J Ophthalmol. 1998;82:845–846
  13. Kuppermann BD, Holland GN. Immune recovery uveitis. Am J Ophthalmol. 2000;130:103–106
  14. Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology. 2006;113:684–694
  15. Holland GN, Pepose JS, Pettit TH, et al. Acquired immune deficiency syndrome (Ocular manifestations). Ophthalmology. 1983;90:859–873
  16. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623–683
  17. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis). Am J Ophthalmol. 1997;124:141–157
  18. Hodge WG, Boivin JF, Shapiro SH, et al. Clinical risk factors for cytomegalovirus retinitis in patients with AIDS. Ophthalmology. 2004;111:1326–1333
  19. Centers for Disease Control and Prevention. Racial/ethnic disparities in diagnoses of HIV/AIDS—33 states, 2001–2004. MMWR Morb Mortal Wkly Rep. 2006;55:121–125
  20. Winker MA. Measuring race and ethnicity: why and how?. JAMA. 2004;292:1612–1614
  21. Voelker R. Women shoulder growing HIV/AIDS burden. JAMA. 2005;293:281–282
  22. Trubo R. CDC initiative targets HIV research gaps in Black and Hispanic communities. JAMA. 2004;292:2563–2564
  23. Butcher RO, Hood RG, Jordan WC. Optimizing treatment for African-Americans and Latinos with HIV/AIDS. J Natl Med Assoc. 2005;97:1093–1100
  24. Wutoh AK, Hidalgo J, Bareta J, et al. Race and the treatment of cytomegalovirus retinitis in a cohort of patients with acquired immunodeficiency syndrome. J Natl Med Assoc. 1998;90:214–220
  25. Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121:466–476
  26. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575–582
  27. Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5:1069–1074
  28. Jacobson MA, Schrier R, McCune JM, et al. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J Infect Dis. 2001;183:1399–1404
  29. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis. 2001;183:1328–1335
  30. Grabar S, Le M, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. V Ann Intern Med. 2000;133:401–410
  31. Lin DY, Warren JF, Lazzeroni LC, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors. Retina. 2002;22:268–277
  32. Davis MG, Kenney SC, Kamine J, et al. Immediate-early gene region of human cytomegalovirus trans- activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987;84:8642–8646
  33. Skolnik PR, Kosloff BR, Hirsch MS. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis. 1988;157:508–514
  34. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827–843
  35. Holland GN, Buhles WC, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy (Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group). Arch Ophthalmol. 1989;107:1759–1766
  36. Gandhi T, Wei W, Amin K, Kazanjian P. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy. Clin Infect Dis. 2006;42:878–884
  37. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55:413–416
  38. Jabs DA, van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1 (Retinitis progression). Ophthalmology. 2004;111:2224–2231
  39. Lagakos SW. The challenge of subgroup analyses—reporting without distorting. N Engl J Med. 2006;354:1667–1669
  40. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel (International AIDS Society-USA). Arch Intern Med. 1998;158:957–969

 Supplemental Material available at AJO.com.

PII: S0002-9394(07)00937-3

doi: 10.1016/j.ajo.2007.09.040

American Journal of Ophthalmology
Volume 145, Issue 1 , Pages 12-22.e10 , January 2008

Article Tools

* Image Usage & Resolution